Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Non-Current Liabilities (2023 - 2025)

Verrica Pharmaceuticals (VRCA) has 3 years of Total Non-Current Liabilities data on record, last reported at $22.4 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 63.51% year-over-year to $22.4 million; the TTM value through Dec 2025 reached $22.4 million, down 63.51%, while the annual FY2025 figure was $22.4 million, 63.51% down from the prior year.
  • Total Non-Current Liabilities reached $22.4 million in Q4 2025 per VRCA's latest filing, down from $56.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $61.8 million in Q4 2023 and bottomed at $6.8 million in Q2 2023.
  • Average Total Non-Current Liabilities over 3 years is $47.1 million, with a median of $55.5 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: decreased 0.79% in 2024, then tumbled 63.51% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $61.8 million in 2023, then dropped by 0.79% to $61.3 million in 2024, then crashed by 63.51% to $22.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $22.4 million in Q4 2025, $56.2 million in Q3 2025, and $54.8 million in Q2 2025.